United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$323.88 USD
-5.37 (-1.63%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $323.46 -0.42 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 541 - 560 ( 596 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
4Q11 Results Review: Revenue Comes in Light; Reiterates Prior 2012 & 2013 Guidance
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4:11 Sales Choppy But FY GAAP EPS Beat. Reiterate OUTPERFORM and $91 FV as Growth Remains Intact, in our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus for Product Sales Is Achievable. Reiterate OUTPERFORM and $91 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Our View The Paragraph IV Certification For Remodulin Is Not A Near-Term Threat To Revenue Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
IV Remodulin Approved in EU and Oral Remodulin NDA Submitted to FDA. Reiterate OUTPERFORM and Raising Fair Value to $91 from $87.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals: December 2011 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
EU Regulatory Progress Offsets Beraprost-MR Program Suspension. Reiterate OUTPERFORM and $87 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
3Q11 Results Review: Solid Quarter as Revenues top Expectations
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Model Update for $250MM Convertible Senior Notes Offering and $212MM Share Repurchase. FV Goes to $87. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-C2 Fails To Hit Primary Endpoint; Downgrading to Hold and Reducing PT
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-C2 Failed; We View Regulatory Risk as High. Due to Failure
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L